Evaluation of Cell-mediated Immune Response by QuantiFERON Monitor® Assay in Kidney Transplant Recipients

Clinical Hospital Merkur

Status: Unknown

Conditions: Kidney Transplant Infection; Kidney Transplant Rejection

Study type: Observational

Funder types: Other

Identifiers

NCT03488771

CHMerkurQFM

Details and patient eligibility

About

All kidney transplant recipients require immunosuppression, the net level of which is difficult to assess. Current practice in assessing immune reactivity is to monitor levels of some immunosuppressive drugs. QuantiFERON Monitor® (QFM) is an in vitro diagnostic test that detects interferon-γ (IFN-γ) release in peripheral blood. Its clinical utility in assessment of the net state of immunosuppression in kidney transplant recipients has not been well studied. The aim of our study is to evaluate the discriminating value of QFM testing results for infection and rejection in a single-centre cohort of kidney transplant recipients.

Enrollment: 150 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Kidney/Liver kidney/Simultaneous pancreas and kidney transplantation

Exclusion criteria

• none

Trial design

150 participants in 3 patient groups

Control

Description:

Kidney transplant recipients without clinical/laboratory/biopsy signs of infection or graft rejection

Infection

Description:

Kidney transplant recipients presenting with clinical or laboratory signs of infection (bacterial or viral)

Rejection

Description:

Kidney transplant recipients presenting with clinical, laboratory or biopsy signs of graft rejection.